Part 3/7:
The earnings reports from Nova Nordisk and Eli Lilly indicated significant demand for GLP-1 products. Nova Nordisk revealed ongoing supply shortages affecting semaglutide, a critical drug for Hims' compounded solutions. This shortage creates an advantageous position for Hims as they can continue offering alternative solutions while the larger pharmaceutical companies struggle to meet demand. Both companies noted capacity limitations that would further prolong these shortages, which bolsters Hims' market presence.